| Assessment Status | Rapid Review Complete |
| HTA ID | 24036 |
| Drug | Dispersible tablet (DT) (dolutegravir sodium, abacavir sulphate, and lamivudine). HTA ID: 24036 |
| Brand | Triumeq® |
| Indication | Triumeq® DT is indicated for Human Immunodeficiency Virus type 1 (HIV-1) infection in children of at least three months of age and weighing at least 6 kg to less than 25 kg |
| Assessment Process | |
| Rapid review commissioned | 13/09/2024 |
| Rapid review completed | 18/10/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Triumeq® DT not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. February 2025
